DNAmic develops therapeutic nanoparticles composed solely of human proteins to enable safe, efficient in‑vivo cell‑targeted delivery of genetic and cellular therapies. By replacing viral vectors and conventional non‑viral systems, their biomimetic platform reduces toxicity and improves targeting, accelerating the development of next‑generation molecular medicines. The modular platform is designed for direct engineering of cells inside the human body, addressing the primary delivery bottleneck in advanced therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Current delivery methods for genetic and cellular therapies rely on viral vectors or conventional non‑viral carriers, which often cause toxicity, have limited targeting specificity, and exhibit low efficiency in reaching diseased cells in vivo.
Solution
DNAmic has created a biomimetic delivery platform that assembles therapeutic nanoparticles exclusively from human proteins. These human‑protein‑based nanoparticles act as natural carriers, reducing immunogenicity and toxicity while improving cell‑type targeting. The modular design enables incorporation of various genetic payloads or therapeutic molecules for precise in‑vivo cell reprogramming. By delivering treatments directly to target cells inside the body, the platform aims to enhance the efficacy of next‑generation molecular medicines without the safety concerns associated with viral vectors.
Target Audience
Primary customers are biotechnology and pharmaceutical companies developing gene, RNA, or cell‑based therapies that require safe and efficient in‑vivo delivery to specific cell populations.
Features
- Nanoparticles composed solely of human proteins, eliminating viral components and minimizing immune response
- Modular architecture allowing customization of surface ligands for selective binding to specific cell types
- Compatibility with a range of therapeutic cargos, including DNA, RNA, and protein therapeutics
- In‑vivo cell‑targeted delivery that enables direct cellular reprogramming within the body
- Scalable, non‑viral manufacturing process that reduces production complexity and toxicity risks